ESTRO 2025 - Abstract Book

S1731

Clinical - Sarcoma & skin cancer & malignant melanoma

ESTRO 2025

Conclusion: This is the largest cohort of patients irradiated after surgical excision of melanoma brain metastases. Postoperative SRT to the resection cavity and concurrent ICI/TKI is an effective and safe treatment for MBM. Yet, MBM patients are at high risk of new BM and require close MRI follow-up. Prospective trials are needed to clarify the possible benefit of the combination.

Keywords: melanoma, immunotherapy, stereotactic radiosurgery

References: 1 Tan XL et al. Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review. Cancers . 2022 Dec 12;14(24):6108. 2 Tan XL et al. Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases. Front Oncol . 2022;12:1025664. 3 Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al . Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med . 2018 Aug 23;379(8):722–30. 4 Davies MA et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial . Lancet Oncol . 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1